Avra is the first company to develop a commercial total synthetic route for the large scale production of Camptothecin derivatives such as Irinotecan (WO/2012/032531 A1, WO/2007/015259 A2) and Topotecan.

Its patented procedures allow for production of these APIs with significantly higher levels of drug purity compared to the existing product forms. Avra supplies Irinotecan intermediates to various domestic and international pharma companies. The company is also developing novel processes for other generic drugs.

Avra has continually invested in its containment technology, controls to ensure safe handling of high potency materials

Avra has segregated high containment facilities and production areas for early stage development, scale-up and commercial manufacture of high-potency drug substance and drug products, with occupational exposure limits (OEL) ranging from 10 μg/m3 down to 1 μg/m3